I-131 Metaiodobenzylguanidine Therapy: It Takes a Village; The Experience Gained at Three Institutions (007)
Despite aggressive treatment, patients with high-risk neuroblastoma have a 40%-60% chance of suffering a relapse. Recent improvements in survival have resulted from changes in treatment during consolidation (tandem myeloablative stem cell transplants) and post-consolidation (immunotherapy) time periods. The neuroblastoma community has been struggling to identify treatments that can be integrated into induction therapy with the goal of further improving survival rates. Consequently, I-131 Metaiodobenzylguanidine (I-131 MIBG) has been moved to the induction treatment period due to its history of success in the treatment of patients with relapsed refractory disease (approximately 40% of patients have a favorable response to treatment with I-131 MIBG).